Literature DB >> 26400057

Can steroidal ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS?

Ya-Qin Wang1, Jin Luo2, Wang-Min Xu3, Qin-Zhen Xie4, Wen-Jie Yan5, Geng-Xiang Wu6, Jin Yang7.   

Abstract

BACKGROUND: Ovarian stimulation in IVF cycle results in luteal supraphysiological steroid concentrations especially for high response patients. The aim of this study was to evaluate the efficacy of ovarian steroid hormone suppression in luteal phase after oocyte retrieval for preventing severe ovarian hyperstimulation syndrome (OHSS) in high-risk patients with embryo cryopreservation.
METHODS: 281 patients with high risk of OHSS were enrolled in this study among 4735 infertile women undergoing their first IVF treatment. The subjects were allocated into treatment and control group. The treatment group (n = 161) received letrozole (n = 43), mifepristone (n = 51), cetrotide (n = 39) and three-drug combinations (n = 28) during the luteal phase after oocyte retrieval, respectively. The control group (n = 120) received no medicine. Fertilization rate, good embryo rate, serum steroid concentration, clinical outcome, and incidence of severe OHSS were compared between the two groups.
RESULTS: On days 2, 5 and 8 after oocyte retrieval, serum estradiol levels in the letrozole and three-drug combination therapy group were significantly lower than in the other three groups at the same time (P < 0.001, respectively). There were no significantly difference of serum luteinizing hormone concentration on days 2, 5 and 8 and progesterone concentration on day 8 after oocyte retrieval among the five groups (P > 0.05, respectively). Compared with the control group, the incidence of severe OHSS, the paracentesis rate, the duration of hospitalization and the days of luteal phase in each subgroup of treatment groups was not significantly decreased (P > 0.05, respectively).
CONCLUSIONS: Our findings indicate that steroidal ovarian suppression in luteal phase after oocyte retrieval seems to be unable to prevent severe OHSS in high-risk patients with embryo cryopreservation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26400057      PMCID: PMC4579791          DOI: 10.1186/s13048-015-0190-y

Source DB:  PubMed          Journal:  J Ovarian Res        ISSN: 1757-2215            Impact factor:   4.234


  39 in total

Review 1.  Embryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists.

Authors:  O Ortmann; J M Weiss; K Diedrich
Journal:  Hum Reprod       Date:  2001-04       Impact factor: 6.918

Review 2.  Prediction of ovarian hyperstimulation syndrome (OHSS). Estradiol level has an important role in the prediction of OHSS.

Authors:  Mohamed Aboulghar
Journal:  Hum Reprod       Date:  2003-06       Impact factor: 6.918

Review 3.  Mechanism and inhibition of cytochrome P-450 aromatase.

Authors:  P A Cole; C H Robinson
Journal:  J Med Chem       Date:  1990-11       Impact factor: 7.446

4.  Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS?

Authors:  Jyotsna Pundir; Sesh Kamal Sunkara; Tarek El-Toukhy; Yacoub Khalaf
Journal:  Reprod Biomed Online       Date:  2011-10-13       Impact factor: 3.828

Review 5.  The ovarian hyperstimulation syndrome.

Authors:  J G Whelan; N F Vlahos
Journal:  Fertil Steril       Date:  2000-05       Impact factor: 7.329

Review 6.  Endocrine and paracrine-autocrine regulation of the human corpus luteum during the mid-luteal phase.

Authors:  L Devoto; M Vega; P Kohen; A Castro; O Castro; L K Christenson; P Carvallo; J F Strauss
Journal:  J Reprod Fertil Suppl       Date:  2000

7.  GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis.

Authors:  G Griesinger; K Diedrich; B C Tarlatzis; E M Kolibianakis
Journal:  Reprod Biomed Online       Date:  2006-11       Impact factor: 3.828

Review 8.  American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

Authors:  Eric P Winer; Clifford Hudis; Harold J Burstein; Rowan T Chlebowski; James N Ingle; Stephen B Edge; Eleftherios P Mamounas; Julie Gralow; Lori J Goldstein; Kathleen I Pritchard; Susan Braun; Melody A Cobleigh; Amy S Langer; Judy Perotti; Trevor J Powles; Timothy J Whelan; George P Browman
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

Review 9.  GnRH antagonists.

Authors:  Maria Elisabetta Coccia; Ciro Comparetto; Gian Luca Bracco; Gianfranco Scarselli
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2004-07-01       Impact factor: 2.435

10.  Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist.

Authors:  T G Lainas; I A Sfontouris; I Z Zorzovilis; G K Petsas; G T Lainas; E M Kolibianakis
Journal:  Reprod Biomed Online       Date:  2007-10       Impact factor: 3.828

View more
  6 in total

Review 1.  The use of gonadotropin-releasing hormone antagonist post-ovulation trigger in ovarian hyperstimulation syndrome.

Authors:  Neil Chappell; William E Gibbons
Journal:  Clin Exp Reprod Med       Date:  2017-06-30

2.  A Prospective Randomised Comparative Clinical Trial Study of Luteal PhaseLetrozole versus Ganirelix Acetate Administration to Prevent Severity of Early Onset OHSS in ARTs.

Authors:  Rana Afzal Choudhary; Priyanka H Vora; Kavita K Darade; Seema Pandey; Kedar N Ganla
Journal:  Int J Fertil Steril       Date:  2021-10-16

3.  Comparison of the Effectiveness of Various Medicines in the Prevention of Ovarian Hyperstimulation Syndrome: A Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Di Wu; Hao Shi; Yiping Yu; Ting Yu; Jun Zhai
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-26       Impact factor: 5.555

4.  High levels estradiol affect blastocyst implantation and post-implantation development directly in mice.

Authors:  Ko-Tung Chang; Yu-Ting Su; Yi-Ru Tsai; Kuo-Chung Lan; Yan-Der Hsuuw; Hong-Yo Kang; Wen-Hsiung Chan; Fu-Jen Huang
Journal:  Biomed J       Date:  2021-01-16       Impact factor: 7.892

Review 5.  Letrozole for Female Infertility.

Authors:  Ai-Min Yang; Na Cui; Yi-Fei Sun; Gui-Min Hao
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-16       Impact factor: 5.555

6.  Whether Letrozole could reduce the incidence of early ovary hyperstimulation syndrome after assisted reproductive technology? A systematic review and meta-analysis.

Authors:  Jing Zhao; Bin Xu; Xi Huang; Yi Yan; Yanping Li
Journal:  Reprod Health       Date:  2020-11-20       Impact factor: 3.223

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.